Sanofi Receives U.S. FDA Approval for Insulin Injection Admelog

By Max Bernhard Features Dow Jones Newswires

Sanofi SA (SAN.FR) received approval for its follow-on mealtime insulin injection Admelog by the U.S. Food and Drug Administration, the company said late Monday.

Continue Reading Below

Admelog will be available in the U.S. in vial form and as a prefilled disposable insulin pen, Sanofi said.

The treatment is a follow-on insulin lispro--a fast-acting insulin--for diabetics who need to manage blood sugar levels at meal times, the company said.

Admelog received authorization from the European Commission in July 2017 to be marketed as a biosimilar under the name Insulin lispro Sanofi.

Write to Max Bernhard at Max.Bernhard@dowjones.com; @mxbernhard

(END) Dow Jones Newswires

Continue Reading Below

December 12, 2017 01:31 ET (06:31 GMT)